Skip to main content

Year: 2021

NewAge Announces New Anti-Aging Discovery and Filing of Patent on New Formula

DENVER, Nov. 16, 2021 (GLOBE NEWSWIRE) — NewAge, Inc. (Nasdaq: NBEV), the Colorado-based direct-to-consumer (D2C) organic and healthy products company, today announced the discovery of a new method of action to fight the effects of aging and the filing of a new patent to protect the uniqueness of the discovery. Following publication in the Journal of Biosciences and Medicine of the recent discovery on how to block spike proteins from binding to human cells, NewAge scientists have filed for a patent that contains multiple unique claims, and a new discovery that supports cardiovascular health and anti-aging. The new discovery encapsulated in the patent includes a powerful new way to unblock the secretion signal from the hypothalamus, thereby stimulating the anterior pituitary gland to naturally secrete human growth hormone (HGH). One...

Continue reading

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

TORONTO, Nov. 16, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research study, titled “Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt SARS-CoV-2 spike complex binding to ACE2 in vitro” from the University of California, San Francisco, showing that potent thiol drugs, like Bucillamine, inhibit SARS-CoV-2 infection in vitro, specifically the Delta variant (B.1.617.2), which is now globally dominant, and also reducing SARS-CoV-2-related lung injury in vivo and providing strong rationale for trials of systemically delivered thiol drugs as COVID-19 treatments. In addition to its anti-oxidant and anti-inflammatory...

Continue reading

Oaktree Specialty Lending Corporation Announces Fourth Fiscal Quarter and Full Year 2021 Financial Results and Declares Increased Distribution of $0.155 Per Share

LOS ANGELES, Nov. 16, 2021 (GLOBE NEWSWIRE) — Oaktree Specialty Lending Corporation (NASDAQ: OCSL) (“Oaktree Specialty Lending” or the “Company”), a specialty finance company, today announced its financial results for the fiscal quarter and year ended September 30, 2021. Financial Highlights for the Quarter and Year Ended September 30, 2021Total investment income was $63.8 million ($0.35 per share) and $209.4 million ($1.29 per share) for the fourth fiscal quarter and full year, respectively, as compared with $65.4 million ($0.36 per share) and $143.1 million ($1.02 per share) for the third fiscal quarter of 2021 and the full year of 2020, respectively. The decrease for the quarter primarily reflected lower prepayment and amendment fees, partially offset by higher interest income and dividend income. The increase for the full...

Continue reading

CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized Rolling Review

Second portion out of three major portions of BLA (CMC portion) will be submitted shortly Clinical section (last portion to complete BLA) expected to be submitted during Q1 2022 VANCOUVER, Washington, Nov. 16, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it has initiated the resubmission of its Biologics License Application (“BLA”) for HIV under rolling review consistent with guidance from the U.S. Food and Drug Administration (“FDA”). Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer, commented, “We are pleased to begin the HIV BLA resubmission process with continued guidance from the FDA. Due to the work of our management...

Continue reading

Aesthetic Medical International Holdings Group Limited Reports Second Quarter and First Half of 2021 Unaudited Financial Results

SHENZHEN, China, Nov. 16, 2021 (GLOBE NEWSWIRE) — Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, today announced its unaudited financial results for the second quarter and first half of 2021. Dr. Zhou Pengwu, Chairman and CEO of the Company, commented, “We are pleased to see an encouraging result in this quarter in terms of (1) operational and financial results, (2) strategic restructuring plan, and (3) our development in the field of non-surgical aesthetic medical services. As the impact of COVID-19 has been gradually receding in mainland China, the public has resumed their daily activities, as well as their consumption of aesthetic medical services. Supported by the recovery of market demand, the number of our active customers...

Continue reading

NRx Pharmaceuticals Reports Third-Quarter 2021 Business Update and Financial Results

Slide taken from a presentation given by Dr. Francis Collins, Director of the National Institutes of Health in September 2021Slide taken from a presentation given by Dr. Francis Collins, Director of the National Institutes of Health in September 2021RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial results. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes before the start of the call by dialing (877) 705-6003...

Continue reading

US Genetic Testing Market to Reach USD 10.29 Billion by 2027 | Market Projection By Technology, Major key players, Growth, Revenue, CAGR, Regional Analysis, Industry Forecast

Key Prominent Players Covered in the US Genetic Testing Market are Invitae Corporation (San Francisco, U.S.), Ambry Genetics (Aliso Viejo, U.S.), BioReference Laboratories, Inc. (Elmwood Park, U.S.), Progenity, Inc. (San Diego, U.S.), Quest Diagnostics Incorporated (Secaucus, U.S.), Myriad Genetics, Inc. (Salt Lake City, U.S.), Fulgent Genetics (Temple City, U.S.), Burning Rock Biotech Limited (Guangzhou, China) Pune, India, Nov. 16, 2021 (GLOBE NEWSWIRE) — The “US Genetic Testing Market” size is expected to experience significant growth by reaching USD 10.29 billion by 2027. Fortune Business Insights in its latest report, titled, “US Genetic Testing Market, 2020-2027.”, observes that the market stood at USD 4.11 billion in 2019 and is projected to exhibit an astounding CAGR of 13.0% between 2020 and 2027. This is attributable...

Continue reading

Global Adult Diapers Market Size is Projected to Reach USD 19.77 Billion by 2026, Exhibiting a CAGR of 7.0% | Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Fortune Business Insights™

Global Adult Diapers Market to Reach $19.77 Billion by 2026; Rising Prevalence of Incontinence to Boost Growth: Fortune Business Insights™ Pune, India, Nov. 16, 2021 (GLOBE NEWSWIRE) — The global adult diapers market is set to gain momentum from the increasing prevalence of incontinence worldwide. The Global Forum on Incontinence states that in 2018, more than 424 million people all over the world were suffering from incontinence. Besides, females are mostly affected by incontinence as compared to males. Fortune Business Insights™ published this information in a recent report, titled, “Adult Diapers Market Size, Share & Industry Analysis, By Product Type (Underwear & Briefs, Pads & Guards, and Drip Collectors & Bed Protectors), By Gender (Male and Female) By Distribution Channel (Institutional Sales, Retail...

Continue reading

Gabriel Holding A/S delivers 11% growth in revenue to a record DKK 810 million. Profit before tax increases by 84% to DKK 59 million.

Selected financial ratiosRevenue increased to DKK 809.7 million (DKK 727.3 million) EBITDA margin was 11.9% (11%) Operating profit (EBIT) was DKK 58.6 million (DKK 41.9 million) EBIT margin was 7.2% (5.8%) Profit before tax was DKK 58.8 million (DKK 32.0 million) Profit after tax was DKK 46.2 million (DKK 25.0 million) Return on invested capital (ROIC) before tax was 13.3% (8.4%)       Earnings per share (EPS) increased to DKK 24.4 (DKK 13.2) Cash flows from operating activities in the period were DKK 39.4 million (DKK 57.2 million) The Board of Directors proposes a dividend of DKK 9.75 per DKK 20 share.Summary Revenue in the financial year was DKK 809.7 million (DKK 727.3 million), an increase of 11%. The realised revenue is the highest in the Group’s 170-year history and thus a record for the seventh consecutive year. The contribution...

Continue reading

Pinduoduo to Report Third Quarter 2021 Unaudited Financial Results on November 26, 2021

SHANGHAI, China., Nov. 16, 2021 (GLOBE NEWSWIRE) — Pinduoduo Inc. (“Pinduoduo”) (NASDAQ: PDD) today announced that it will report its unaudited financial results for the third quarter ended September 30, 2021, before U.S. markets open on Friday, November 26, 2021. Pinduoduo’s management will hold an earnings conference call at 7:30 AM U.S. Eastern Time on November 26, 2021 (8:30 PM Beijing/Hong Kong Time on the same day). The conference call will be webcast live at https://investor.pinduoduo.com/investor-events. The webcast will be available for replay at the same website following the conclusion of the call. About Pinduoduo Inc. Pinduoduo is a mobile-only marketplace that connects millions of agricultural producers with consumers across China. Pinduoduo aims to bring more businesses and people into the digital economy so that...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.